We scan new podcasts and send you the top 5 insights daily.
A key investment criterion is capital efficiency, defined as current revenue being greater than all historical cash burned since inception. This "one-to-one ratio" acts as a proxy for return on equity and identifies businesses with strong underlying models, keeping the firm out of trouble.
The firm's primary KPI is maintaining 95% gross dollar retention from its limited partners. This singular focus forces discipline in generating consistent investment returns and providing world-class client service, as both are required to hit the target.
Founders can become fixated on achieving a good burn multiple, which is a theoretical measure of fundability. However, they sometimes forget the practical reality: a great burn multiple is useless if the company runs out of cash. Cash in the bank is a material construct, not a theoretical one.
Methodical Investments' rule to only hold profitable companies serves a dual purpose. Beyond seeking better performance, it ensures data integrity for their models. Metrics like P/E become more reliable and comparable across the portfolio when the denominator (earnings) is consistently positive, avoiding statistical noise from unprofitable firms.
For pre-revenue biotech firms, value can be anchored to total cash spent on R&D and operations, not profits. A lower market cap relative to this cumulative "spend" indicates a cheaper company, flipping the traditional value investing mindset on its head and providing a powerful quantitative factor.
While AI-native companies burn cash at alarming rates (e.g., -126% free cash flow), their extreme growth results in superior burn multiples. They generate more ARR per dollar burned than non-AI companies, making them highly attractive capital-efficient investments for VCs despite the high absolute burn.
The burn multiple, a classic SaaS efficiency metric, is losing its reliability. Its underlying assumptions (stable margins, low churn, no CapEx) don't hold for today's fast-growing AI companies, which have variable token costs and massive capital expenditures, potentially hiding major business risks.
The true differentiator for top-tier companies isn't their ability to attract investors, but how efficiently they convert invested capital into high-margin, high-growth revenue. This 'capital efficiency' is the key metric Karmel Capital uses to identify elite performers among a universe of well-funded businesses.
LeadEdge Capital's famous "Hierarchy of Bullshit," which prioritizes cash profits over vanity metrics, originated from the founders' early experience cold calling thousands of companies. This volume created deep pattern recognition for what separates a good business from noise.
Instead of focusing on vague metrics like management or margins, the primary measure of a "good business" should be its fundamental return on invested capital (ROIC). This first-principles, quantitative approach is the foundation for sound credit underwriting, especially in illiquid deals.
After a premature growth spurt failed, Nexla's founders reset by taking no salaries and implementing a strict rule: new team members were only added when new customer revenue could justify the cost. This forced discipline led them to become cash-flow positive with multi-seven-figure revenue before their Series A.